{
    "organizations": [],
    "uuid": "87d5def4936c18947aa96655bdd491ec17094871",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-teva-reports-q1-non-gaap-earnings/brief-teva-reports-q1-non-gaap-earnings-per-share-0-94-idUSASC09ZGA",
    "ord_in_thread": 0,
    "title": "Teva Reports Q1 Non-GAAP Earnings Per Share $0.94",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 3 (Reuters) - Teva Pharmaceutical Industries Ltd :\n* TEVA REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS * Q1 NON-GAAP EARNINGS PER SHARE $0.94\n* RAISING 2018 FULL YEAR GUIDANCE * RESTRUCTURING PLAN ON-TRACK TO ACHIEVE $1.5 BILLION OF SAVINGS IN 2018 AND $3.0 BILLION BY END OF 2019\n* 2018 FREE CASH FLOW GUIDANCE RAISED TO $3.0-3.2 BILLION FROM $2.6-2.8 BILLION\n* 2018 NON-GAAP EPS GUIDANCE RAISED TO $2.40-2.65 FROM $2.25-2.50\n* COPAXONE REVENUES IN OUR NORTH AMERICA SEGMENT IN Q1 OF 2018 DECREASED BY 40% TO $476 MILLION\n* COPAXONE REVENUES IN OUR EUROPE SEGMENT IN Q1 OF 2018 INCREASED BY 1% TO $153 MILLION\n* SEES 2018 REVENUES $18.5 BILLION TO $19.0 BILLION * TEVA PHARMACEUTICAL INDUSTRIES - GENERIC PRODUCTS REVENUE IN NORTH AMERICA SEGMENT IN Q1 2018 FELL BY 23% TO $1.1 BILLION, COMPARED TO Q1 OF 2017\n* TEVA PHARMACEUTICAL - DO NOT EXPECT TO RECEIVE FDA APPROVAL ON BIOLOGICS LICENSE APPLICATIONS (BLA) FOR FREMANEZUMAB ON MID-JUNE PDUFA DATE\n* TEVA PHARMACEUTICAL INDUSTRIES - GENERIC PRODUCTS REVENUE IN EUROPE SEGMENT IN Q1 2018, INCLUDING OTC PRODUCTS, ROSE 17% TO $997 MILLION, VERSUS Q1 2017\n* TEVA - REGARDING FREMANEZUMAB, CO SEES FDA PRE-APPROVAL INSPECTION TO TAKE PLACE IN COMING MONTHS & TO RECEIVE FDA APPROVAL & LAUNCH BEFORE 2018 END Source text for Eikon:\nOur ",
    "published": "2018-05-03T19:20:00.000+03:00",
    "crawled": "2018-05-04T16:32:32.042+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "teva",
        "pharmaceutical",
        "industry",
        "ltd",
        "teva",
        "report",
        "first",
        "quarter",
        "financial",
        "result",
        "q1",
        "earnings",
        "per",
        "share",
        "raising",
        "full",
        "year",
        "guidance",
        "restructuring",
        "plan",
        "achieve",
        "billion",
        "saving",
        "billion",
        "end",
        "free",
        "cash",
        "flow",
        "guidance",
        "raised",
        "billion",
        "billion",
        "eps",
        "guidance",
        "raised",
        "copaxone",
        "revenue",
        "north",
        "america",
        "segment",
        "q1",
        "decreased",
        "million",
        "copaxone",
        "revenue",
        "europe",
        "segment",
        "q1",
        "increased",
        "million",
        "see",
        "revenue",
        "billion",
        "billion",
        "teva",
        "pharmaceutical",
        "industry",
        "generic",
        "product",
        "revenue",
        "north",
        "america",
        "segment",
        "q1",
        "fell",
        "billion",
        "compared",
        "q1",
        "teva",
        "pharmaceutical",
        "expect",
        "receive",
        "fda",
        "approval",
        "biologics",
        "license",
        "application",
        "bla",
        "fremanezumab",
        "pdufa",
        "date",
        "teva",
        "pharmaceutical",
        "industry",
        "generic",
        "product",
        "revenue",
        "europe",
        "segment",
        "q1",
        "including",
        "otc",
        "product",
        "rose",
        "million",
        "versus",
        "q1",
        "teva",
        "regarding",
        "fremanezumab",
        "co",
        "see",
        "fda",
        "inspection",
        "take",
        "place",
        "coming",
        "month",
        "receive",
        "fda",
        "approval",
        "launch",
        "end",
        "source",
        "text",
        "eikon"
    ]
}